Ortho-mcneil Pharmaceutical Corp.

Affymax Technologies, N.v.

Linda Mulcahy

Linda K Jolliffe

Allen B Reitz

William V Murray

Cynthia Anne Maryanoff

Frank John Villani, Jr

Xiaobing Li

Virginia L Pulito

William J Dower

Nicholas C Wrighton

Arun K Kashyap

Ray S Chang

Dana Johnson

This invention relates to a series of arylsubstituted piperazines, of Formula Ipharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &#x3b1;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.

Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia

This invention relates to a series of arylsubstituted piperazines, of Formula I ##STR1## pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the .alpha.-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.

Arylsubstituted piperazines useful in the treatment of benign prostatic

Peptides of 10 to 40 or more amino acid residues in length and having the sequence X.sub.3 X.sub.4 X.sub.5 GPX.sub.6 TWX.sub.7 X.sub.8 (SEQ ID NO:252) where each amino acid is indicated by standard one letter abbreviation; X.sub.3 is C; X.sub.4 is R, H, L, or W; X.sub.5 is M, F, or I; X.sub.6 is independently selected from any one of the 20 genetically coded L-amino acids; X.sub.7 is D, E, I, L, or V; and X.sub.8 is C, which bind and activate the erythropoietin receptor (EPO-R) or otherwise act as an EPO agonist, and methods for their use.

Compounds and peptides that bind to the erythropoietin receptor

Growing community of inventors

Flemington, NJ, United States of America

Linda Mulcahy